Last 48 quarters of trend data · Healthcare · Metabolic & Cardiovascular Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.73 | 6.54 | 11.07 | 7.49 | 6.28 | 4.14 | 3.74 | 3.20 | 5.09 | 7.70 | 6.35 | 9.08 | 5.35 | 3.00 | 4.16 | 9.73 | 4.95 | 1.38 | 1.35 | 1.27 | 1.75 |
| — | +57.9% | +196.5% | +134.5% | +23.3% | -46.3% | -41.2% | -64.8% | -4.8% | +156.7% | +52.9% | -6.6% | +7.9% | +118.2% | +208.5% | +663.7% | +182.7% | -40.2% | -35.0% | -36.1% | +4.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -47.3% | -36.8% | -28.1% | -27.8% | -23.3% | -12.0% | -8.0% | -5.3% | -4.0% | -2.7% | -2.4% | -4.3% | -6.9% | -6.0% | -7.4% | -14.0% | -13.2% | -10.0% | -10.0% | -8.4% | -6.0% |
| — | -205.3% | -252.3% | -425.3% | -489.9% | -342.2% | -232.8% | -23.8% | +42.4% | +54.4% | +67.5% | +69.5% | +47.9% | +40.1% | +26.3% | -66.8% | -121.5% | -64.9% | -50.7% | -44.1% | -35.5% | |
| ROA | -44.3% | -24.4% | -22.7% | -23.9% | -21.7% | -11.6% | -7.7% | -5.1% | -3.8% | -2.6% | -2.3% | -4.1% | -6.6% | -5.8% | -7.0% | -12.2% | -11.7% | -9.1% | -9.3% | -7.9% | -5.7% |
| — | -111.0% | -192.8% | -365.3% | -464.8% | -337.8% | -232.8% | -25.5% | +41.4% | +54.0% | +66.7% | +66.5% | +43.9% | +36.5% | +24.7% | -54.0% | -105.5% | -58.1% | -46.9% | -43.5% | -34.9% | |
| ROIC | -44.4% | -62.0% | -29.7% | -28.7% | -22.7% | -10.7% | -7.1% | -5.0% | -4.0% | -3.2% | -3.2% | -4.9% | -7.0% | -6.3% | -8.2% | -13.5% | -13.0% | -8.9% | -8.2% | -7.0% | -5.0% |
| — | -477.4% | -317.0% | -474.6% | -462.9% | -241.1% | -125.3% | -1.1% | +42.4% | +49.9% | +61.4% | +63.5% | +46.1% | +29.0% | +0.3% | -92.9% | -161.8% | -84.4% | -53.9% | -43.6% | -37.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.43 | 0.01 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| — | +40760.4% | +806.4% | — | -83.2% | -21.8% | -7.5% | -6.6% | -64.9% | -62.7% | -67.4% | -88.6% | -66.4% | -66.4% | -63.4% | +23.5% | +7373.6% | +1902.6% | +1036.1% | +665.1% | -90.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.33 | 7.27 | 4.72 | 5.72 | 9.33 | 28.34 | 25.86 | 44.25 | 33.09 | 36.47 | 37.69 | 29.48 | 19.19 | 28.44 | 29.63 | 9.55 | 7.61 | 11.74 | 12.10 | 17.15 | 23.98 |
| — | -74.4% | -81.7% | -87.1% | -71.8% | -22.3% | -31.4% | +50.1% | +72.4% | +28.2% | +27.2% | +208.7% | +152.1% | +142.2% | +144.9% | -44.3% | -68.3% | -40.5% | -34.5% | -11.3% | +13.6% | |
| Quick Ratio | 9.33 | 7.27 | 4.72 | 5.72 | 9.33 | 28.34 | 25.86 | 44.25 | 33.09 | 36.47 | 37.69 | 29.48 | 19.19 | 28.44 | 29.63 | 9.55 | 7.61 | 11.74 | 12.10 | 17.15 | 23.98 |
| — | -74.4% | -81.7% | -87.1% | -71.8% | -22.3% | -31.4% | +50.1% | +72.4% | +28.2% | +27.2% | +208.7% | +152.1% | +142.2% | +144.9% | -44.3% | -68.3% | -40.5% | -34.5% | -11.3% | +13.6% | |
| Interest Coverage | — | -2080.66 | — | — | — | -11347.38 | -2730.71 | -1900.21 | -1474.71 | -1038.17 | -1235.11 | -976.00 | -945.35 | -11266.00 | -599.78 | -696.54 | -2443.88 | -583.19 | -1451.67 | — | -1028.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VKTX stock.
Viking Therapeutics, Inc.'s current P/E is -5.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Viking Therapeutics, Inc.'s business trajectory between earnings reports.